Sandy Macrae | President and Chief Executive Officer
Sangamo BioSciences, Inc

Sandy Macrae, President and Chief Executive Officer, Sangamo BioSciences, Inc

Dr. Sandy Macrae serves as Sangamo’s President and CEO and as a member of the Board of Directors. He has twenty years of experience in the pharmaceutical industry previously serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets R&D. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr. Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.

Appearances:



World Orphan Drug Congress USA 2018 - Conference Day Two (General) @ 08:35

Keynote address: Developing genomic medicines and the first ever in- vivo human genome editing trials using zinc finger nucleases

  • Gene therapy, genome editing, cell therapy, gene regulation: choosing the best therapeutic platform to address a patient’s needs
  • Editing liver cells with ZFNs to potentially cure rare diseases, including MPS I, MPS II and hemophilia B
  • Zinc finger nuclease technology vs. CRISPR-Cas9: what’s important when developing genomic medicines
  • Zinc finger nucleases as a best-in-class tool to make cell therapies for cancer – Sangamo’s goal of allogeneic cell-based immuno-therapies
  • The next frontier: what does the future of genome editing look like? Delivery, capabilities, safety, ethics, etc

back to speakers